Date: May. 25	th , 2021
Your Name:	Huipeng Meng
Manuscript Tit	le: Feasibility evaluation of KV-CBCT dose calculation following scatter correction: investigations of
phantom and i	representative tumor sites
Manuscript nu	mber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Huipeng MengNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Huipeng MengNone	
3	Royalties or licenses	Huipeng MengNone	
4	Consulting fees	Huipeng MengNone	

5	Payment or honoraria for lectures, presentations,	Huipeng Meng_None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	Huipeng MengNone	
	testimony		
7	Compant for attanding	Huinana Mana Mana	
,	Support for attending meetings and/or travel	Huipeng MengNone	
8	Patents planned, issued or	Huipeng MengNone	
	pending		
0	Doubleinstien en e Dete	Huinana Mana Mana	
9	Participation on a Data Safety Monitoring Board or	Huipeng MengNone	
	Advisory Board		
10	Leadership or fiduciary role	Huipeng Meng_None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	Huipeng Meng None	
11	Stock or stock options	Huipeng Meng_None	
12	Receipt of equipment,	Huipeng MengNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	Huipeng MengNone	
	financial interests		
DIa	ease summarize the above o	anflict of interest in the fo	lowing hov
rit	ase summanze the above t	omaci of interest in the lo	IOWING DOX.
	None.		

None.			

__ Huipeng Meng_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: May. 25th,	2021
Your Name:	Xiangjuan Meng
Manuscript Title:	Feasibility evaluation of KV-CBCT dose calculation following scatter correction: investigations of
phantom and rep	presentative tumor sites
Manuscript num	ber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Xiangjuan Meng_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Xiangjuan Meng_None	
3	Royalties or licenses	Xiangjuan Meng_None	
4	Consulting fees	Xiangjuan MengNone	

5	Payment or honoraria for	Xiangjuan MengNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \			
6	Payment for expert	Xiangjuan MengNone			
	testimony				
7	Cupport for attending	Viangiuan Mang Nana			
/	Support for attending meetings and/or travel	Xiangjuan MengNone			
	meetings and/or traver				
8	Patents planned, issued or	Xiangjuan MengNone			
	pending				
9	Participation on a Data	Xiangjuan MengNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	Xiangjuan MengNone			
	in other board, society,				
	committee or advocacy group, paid or unpaid				
11	Stock or stock options	Xiangjuan Meng_None			
	•	<u> </u>			
12	Receipt of equipment,	Xiangjuan MengNone			
	materials, drugs, medical				
	writing, gifts or other				
	services	\(\text{\tint{\text{\tin}\text{\ti}\\\ \text{\text{\text{\text{\text{\text{\text{\text{\tin}\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\tin}\text{\text{\text{\text{\text{\text{\text{\text{\text{\ti}\tint{\text{\text{\text{\text{\text{\tin}\tint{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\texi}\\ \titt}\\\ \tinttitex{\text{\text{\text{\text{\text{\text{\text{\texi}\text{\text{\text{\text{\texi}\tilitt{\text{\texi}\tint{\text{\text{\text{\text{\text{\texi}\tint{\text{\texi}\			
13	Other financial or non- financial interests	Xiangjuan MengNone			
	illialiciai liiterests				
Ple	Please summarize the above conflict of interest in the following box:				

None.			

__ Xiangjuan Meng_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: May. 25th	, 2021
Your Name:	Qingtao Qiu
Manuscript Title	e: Feasibility evaluation of KV-CBCT dose calculation following scatter correction: investigations of
phantom and re	epresentative tumor sites
Manuscript nun	nber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Qingtao QiuNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Qingtao QiuNone	
3	Royalties or licenses	Qingtao QiuNone	
4	Consulting fees	Qingtao QiuNone	

5	Payment or honoraria for	Qingtao QiuNone				
	lectures, presentations,					
	speakers bureaus,					
	manuscript writing or					
	educational events					
6	Payment for expert	Qingtao QiuNone				
	testimony					
_						
7	Support for attending	Qingtao QiuNone				
	meetings and/or travel					
8	Patents planned, issued or	Qingtao QiuNone				
	pending					
9	Participation on a Data	Qingtao QiuNone				
	Safety Monitoring Board or					
	Advisory Board					
10	Leadership or fiduciary role	Qingtao QiuNone				
	in other board, society,					
	committee or advocacy					
	group, paid or unpaid					
11	Stock or stock options	Qingtao QiuNone				
12	Receipt of equipment,	Qingtao QiuNone				
	materials, drugs, medical					
	writing, gifts or other					
	services					
13	Other financial or non-	Qingtao QiuNone				
	financial interests					
Ple	Please summarize the above conflict of interest in the following box:					

None.			

__ Qingtao Qiu_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: May. 25 th , 2021
Your Name: Yanlong Zhang
Manuscript Title: Feasibility evaluation of KV-CBCT dose calculation following scatter correction: investigations of
phantom and representative tumor sites
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Yanlong ZhangNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Yanlong ZhangNone	
3	Royalties or licenses	Yanlong ZhangNone	
4	Consulting fees	Yanlong ZhangNone	

5	Payment or honoraria for lectures, presentations,	Yanlong ZhangNone				
	speakers bureaus,					
	manuscript writing or					
	educational events					
6	Payment for expert	Yanlong ZhangNone				
	testimony					
-	C	V 1 71 N				
7	Support for attending meetings and/or travel	Yanlong ZhangNone				
8	Patents planned, issued or	Yanlong ZhangNone				
	pending					
9	Participation on a Data	Yanlong ZhangNone				
	Safety Monitoring Board or Advisory Board					
10	Leadership or fiduciary role	Yanlong Zhang_None				
10	in other board, society,	Tarrioris ZirarisNorie				
	committee or advocacy					
	group, paid or unpaid					
11	Stock or stock options	Yanlong ZhangNone				
12	Receipt of equipment,	Vanlang Thang Nana				
12	materials, drugs, medical	Yanlong ZhangNone				
	writing, gifts or other					
	services					
13	Other financial or non-	Yanlong ZhangNone				
	financial interests					
	Please summarize the above conflict of interest in the following box:					

None.			

__ Yanlong Zhang_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: May. 25t	^h , 2021
Your Name:	Xin Ming
Manuscript Titl	e: Feasibility evaluation of KV-CBCT dose calculation following scatter correction: investigations of
phantom and r	epresentative tumor sites
Manuscrint nu	mber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Xin Ming_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Xin Ming_None	
3	Royalties or licenses	Xin Ming_None	
4	Consulting fees	Xin MingNone	

		T	
5	Payment or honoraria for	Xin MingNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	Xin MingNone	
	testimony		
7	Support for attending	Xin Ming_None	
	meetings and/or travel	<u> </u>	
8	Patents planned, issued or	Xin MingNone	
•	pending	78	
	P		
9	Participation on a Data	Xin MingNone	
	Safety Monitoring Board or	<u> </u>	
	Advisory Board		
10	Leadership or fiduciary role	Xin Ming_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	Xin MingNone	
12	Receipt of equipment,	Xin MingNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	Xin MingNone	
	financial interests		
DIA	aca cummariza tha abaya c	anflict of interact in the	following how

None.			

Please place an "X" next to the following statement to indicate your agreement:

__ Xin Ming_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: May. 25th	, 2021
Your Name:	Qifeng Li
Manuscript Title	e: Feasibility evaluation of KV-CBCT dose calculation following scatter correction: investigations of
phantom and re	presentative tumor sites
Manuscrint nun	pher (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Qifeng LiNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Qifeng LiNone	
3	Royalties or licenses	Qifeng LiNone	
4	Consulting fees	Qifeng LiNone	

5	Payment or honoraria for	Qifeng LiNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	Qifeng LiNone	
	testimony		
	·		
7	Support for attending	Qifeng Li None	
	meetings and/or travel		
	5 ,		
8	Patents planned, issued or	Qifeng LiNone	
	pending		
	1 · · · · · · · · · · · · · · · · · · ·		
9	Participation on a Data	Qifeng LiNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	Qifeng LiNone	
	in other board, society,	<u> </u>	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	Qifeng Li_None	
12	Receipt of equipment,	Qifeng LiNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	Qifeng LiNone	
	financial interests		

None.			

Please place an "X" next to the following statement to indicate your agreement:

__ Qifeng Li_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: May. 25th	^h , 2021
Your Name:	Kegiang Wang
Manuscript Title	e: Feasibility evaluation of KV-CBCT dose calculation following scatter correction: investigations of
phantom and re	epresentative tumor sites
Manuscrint nur	mber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Keqiang WangNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Keqiang WangNone	
3	Royalties or licenses	Keqiang WangNone	
4	Consulting fees	Keqiang WangNone	

5	Payment or honoraria for lectures, presentations,	Keqiang WangNone	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert	Keqiang WangNone	
	testimony		
7	Support for attending meetings and/or travel	Keqiang Wang_None	
8	Patents planned, issued or	Keqiang WangNone	
	pending		
9	Participation on a Data	Keqiang WangNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	Keqiang WangNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	Keqiang WangNone	
12	Receipt of equipment,	Keqiang Wang_None	
	materials, drugs, medical	Median's rrang_rrane	
	writing, gifts or other services		
13	Other financial or non-	Keqiang WangNone	
	financial interests		
Plo	ease summarize the above o	conflict of interest in the fo	llowing box:
- 1	None.		

__ Keqiang Wang_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: <u>May. 25th</u>	, 2021
Your Name:	Ruohui Zhang
Manuscript Title	e: Feasibility evaluation of KV-CBCT dose calculation following scatter correction: investigations of
phantom and re	epresentative tumor sites
Manuscript nun	nber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Ruohui Zhang_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Ruohui Zhang_None	
3	Royalties or licenses	Ruohui ZhangNone	
4	Consulting fees	Ruohui ZhangNone	

			·
5	Payment or honoraria for lectures, presentations,	Ruohui ZhangNone	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	Ruohui ZhangNone	
	testimony		
	•		
7	Support for attending meetings and/or travel	Ruohui ZhangNone	
8	Patents planned, issued or	Ruohui ZhangNone	
	pending		
9	Participation on a Data	Ruohui Zhang None	
9	Safety Monitoring Board or	Ruonui Ziiangivone	
	Advisory Board		
10	Leadership or fiduciary role	Ruohui ZhangNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	Ruohui Zhang_None	
4.2	D	D 1 : 71 N	
12	Receipt of equipment, materials, drugs, medical	Ruohui ZhangNone	
	writing, gifts or other		
	services		
13	Other financial or non-	Ruohui ZhangNone	
	financial interests		

None.			

Please place an "X" next to the following statement to indicate your agreement:

__ Ruohui Zhang_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: May.	25 th , 2021
Your Name:	Jinghao Duan
Manuscript	Title: Feasibility evaluation of KV-CBCT dose calculation following scatter correction: investigations of
phantom an	nd representative tumor sites
Manuscrint	number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Jinghao DuanNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Jinghao DuanNone	
3	Royalties or licenses	Jinghao DuanNone	
4	Consulting fees	Jinghao DuanNone	

5	Payment or honoraria for	Jinghao DuanNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	Jinghao DuanNone	
	testimony		
7	Support for attending	Jinghao DuanNone	
	meetings and/or travel		
	Datasta alasand issued as	Backer Door Many	
8	Patents planned, issued or	Jinghao DuanNone	
	pending		
9	Participation on a Data	Jinghao DuanNone	
9	Safety Monitoring Board or	Jiligilao DualiNone	
	Advisory Board		
10	Leadership or fiduciary role	Jinghao DuanNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	Jinghao DuanNone	
12	Receipt of equipment,	Jinghao DuanNone	
	materials, drugs, medical		
	writing, gifts or other		
10	services		
13	Other financial or non-	Jinghao DuanNone	
	financial interests		
ы.			H

None.			

Please place an "X" next to the following statement to indicate your agreement:

__ Jinghao Duan_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.